scholarly journals Potential Therapeutic Effects of Underground Parts ofKalanchoe gastonis-bonnierion Benign Prostatic Hyperplasia

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Antonio Palumbo ◽  
Livia Marques Casanova ◽  
Maria Fernanda Paresqui Corrêa ◽  
Nathalia Meireles Da Costa ◽  
Luiz Eurico Nasciutti ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Stromal Cells ◽  
Prostate Gland ◽  
Herbal Medicines ◽  
Syringic Acid ◽  
Pharmacological Therapy ◽  
Prostatic Hyperplasia ◽  
Therapeutic Effects ◽  
Complex Chemical Composition ◽  
Old Men

Benign Prostatic Hyperplasia (BPH) affects mainly older men. It is estimated to affect 50% of 51-60-year-old men and 70% of 61-70-year-old men. BPH is a nonmalignant proliferation of epithelial and stromal cells of the prostate gland regions. Despite the use of conventional pharmacological therapy, herbal medicines are used in BPH therapy, and several mechanisms of action have been suggested based on their complex chemical composition. Considering the ethnomedicinal uses ofKalanchoe gastonis-bonnieri(KGB), we evaluated the inhibitory effects on the proliferation of stromal cells from primary benign prostatic hyperplasia (BPH) of four different aqueous extracts from this plant: underground parts from specimens in flower (T1 treatment), leaves from specimens in flower (T2 treatment), and flowers (T3 treatment) and leaves from specimens not in flower (T4 treatment). T1, T2, T3, and T4 treatments at 250μg/ml for 72 hours inhibited BPH cells by 56.7%, 29.2%, 39.4%, and 13.5%, respectively, showing that the KGB underground parts extract (T1 treatment) was the most active. Our findings show that the extract of the KGB underground parts (150 and 250μg/ml) stimulates important changes in the BPH cells, modulating crucial processes such as proliferation, viability, and apoptosis. HPLC-DAD-MS/MS analysis provided a tentative identification of glycosylated syringic acid derivatives, glycosylated forms of volatile compounds, and lignans in this extract. Finally, these results suggest that there is a potential therapeutic use for KGB in BPH, which could improve the clinical management of the disease.

scholarly journals Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Fatemeh Akbari ◽  
Mohammad Azadbakht ◽  
Kanu Megha ◽  
Ayat Dashti ◽  
Lale Vahedi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Wistar Rats ◽  
Histopathological Examination ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Vehicle Group ◽  
Common Disease ◽  
Therapeutic Effects ◽  
Juniperus Communis ◽  
Male Wistar Rats

Abstract Background Benign prostatic hyperplasia (BPH) is a common disease which causes various health problems for elderly men such as urinary retention, recurring urinary tract infection and bladder stones. The aim of this study is to evaluate the therapeutic effects of Juniperus communis L. seed extract (JCS) on BPH in male Wistar rats. Methods To this end, 30 rats were divided into 5 groups (N = 6): group 1 (vehicle), group 2 (disease control), group 3 (standard medicine; 10 mg/kg finasteride), and groups 4 and 5 were treated with 300 mg/kg and 600 mg/kg of the hydroalcoholic JCS seed extract, respectively. Groups 2, 3, 4 and 5 received testosterone enanthate to induce prostatic hyperplasia. At the end of experimental period (28 days), prostate glands were cut off under anesthesia. Histopathological examination was done and biochemical parameters such as Malondialdehyde, Glutathione and protein carbonyl were also measured. Their body weights were also observed during the study. At the end of the experiment, prostate weights and prostate specific antigen (PSA) levels were measured. Prostate index, inhibition prostate weight and inhibition prostate index were also calculated. Results Both histopathological examination and biochemical parameter results showed significant improvements in rats treated with finasteride and 600 mg/kg JCS extract (p < 0.01). In addition, PSA levels showed significant decrease in comparison with the disease group. But acute toxicity test indicated that using JCS extract resulted in an increase in liver enzymes (ALP, LDH, SGOT, SGPT). As a result, the extract should be used with caution. Conclusions Oral administration of JCS extract is effective on preventing testosterone-induced benign prostatic hyperplasia.

Diseases of the prostate

2004 ◽  
Vol 14 (2) ◽  
pp. 119-128
Author(s):  
A Cannon ◽  
P Abrams
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostate Gland ◽  
Prostatic Hyperplasia ◽  
Histological Diagnosis ◽  
British Association ◽  
International Continence Society ◽  
Elderly Men ◽  
International Consultation ◽  
Stromal Tissue

Benign enlargement of the prostate gland does not always cause symptoms or obstruction to the flow of urine. Old terminology, for example, ‘prostatism’ can therefore be misleading, and the British Association of Urological Surgeons (BAUS), the International consultation on BPH and the International Continence Society accept the definitions given below:Benign prostatic hyperplasia (BPH) is a histological diagnosis. The first pathological signs appear under the age of 40 years, followed by a rapid increase in prevalence with age; 80% of 80-year-olds have evidence of BPH. The onset of BPH is dependent on the presence of functioning testes and increasing age. It is characterized by a combination of atrophy and proliferation in both glandular and stromal tissue. Although BPH is detectable in most elderly men, it does not always cause enlargement of the prostate, symptoms, or obstruction to the flow of urine.

Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property

The Prostate ◽  
2007 ◽  
Vol 67 (12) ◽  
pp. 1265-1276 ◽  
Author(s):  
Victor K. Lin ◽  
Shih-Ya Wang ◽  
Dolores V. Vazquez ◽  
Chet C. Xu ◽  
Sheng Zhang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Benign Prostatic Hyperplasia ◽  
Stromal Cells ◽  
Prostatic Hyperplasia

scholarly journals Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

2012 ◽  
Vol 214 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Linda Vignozzi ◽  
Ilaria Cellai ◽  
Raffaella Santi ◽  
Letizia Lombardelli ◽  
Annamaria Morelli ◽  
...  
Keyword(s):  
T Cells ◽  
Growth Factors ◽  
Androgen Receptor ◽  
Benign Prostatic Hyperplasia ◽  
Stromal Cells ◽  
Receptor Activation ◽  
Prostatic Hyperplasia ◽  
Serum Testosterone Level ◽  
Antiinflammatory Effect ◽  
Inflammatory Growth

Progression of benign prostatic hyperplasia (BPH) involves chronic inflammation and immune dysregulation. Preclinical studies have demonstrated that prostate inflammation and tissue remodeling are exacerbated by hypogonadism and prevented by testosterone supplementation. We now investigated whether, in humans, hypogonadism was associated with more severe BPH inflammation and the in vitro effect of the selective androgen receptor agonist dihydrotestosterone (DHT) on cultures of stromal cells derived from BPH patients (hBPH). Histological analysis of inflammatory infiltrates in prostatectomy specimens from a cohort of BPH patients and correlation with serum testosterone level was performed. Even after adjusting for confounding factors, hypogonadism was associated with a fivefold increased risk of intraprostatic inflammation, which was also more severe than that observed in eugonadal BPH patients. Triggering hBPH cells by inflammatory stimuli (tumor necrosis factor α, lipopolysaccharide, or CD4+T cells) induced abundant secretion of inflammatory/growth factors (interleukin 6 (IL6), IL8, and basic fibroblast growth factor (bFGF)). Co-culture of CD4+T cells with hBPH cells induced secretion of Th1 inducer (IL12), Th1-recruiting chemokine (interferon γ inducible protein 10, IP10), and Th2 (IL9)- and Th17 (IL17)-specific cytokines. Pretreatment with DHT inhibited NF-κB activation and suppressed secretion of several inflammatory/growth factors, with the most pronounced effects on IL8, IL6, and bFGF. Reduced inflammatory cytokine production by testosterone cells, an increase in IL10, and a significant reduction of testosterone cells proliferation suggested that DHT exerted a broad antiinflammatory effect on testosterone cells. In conclusion, our data demonstrate that DHT exerts an immune regulatory role on human prostatic stromal cells, inhibiting their potential to actively induce and/or sustain autoimmune and inflammatory responses.

scholarly journals Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Yanbo Chen ◽  
Hui Xu ◽  
Chong Liu ◽  
Meng Gu ◽  
Qi Chen ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin D ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Therapeutic Effects ◽  
Prostate Cell ◽  
Mesenchymal Transition ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

The pathogenesis of benign prostatic hyperplasia (BPH) is extremely complicated which involving the multiple signaling pathways. The deficiency of vitamin D is an important risk factor for BPH, and exogenous vitamin D is effective for the treatment of BPH. In this study, we provided in vitro mechanical evidence of vitamin D as a treatment for BPH using BPH-1, WPMY-1, and PBMC cells. We found that 25-hydroxyvitamin D (25-OH D) level is decreased in BPH and closely correlated with age, prostate volume, maximum flow, international prostate symptom score, and prostate-specific antigen of the BPH patients. We further revealed that 25-OH D ameliorated TGF-β1 induces epithelial-mesenchymal transition (EMT) of BPH-1 cells and proliferation of WPMY-1 cells via blocking TGF-β signaling. Moreover, 25-OH D was able to block NF-κB signaling in PBMCs of BPH patients and STAT3 signaling in BPH cells to relieve inflammation. 25-OH D also protects BPH cells from inflammatory cytokines selected by PBMCs. Finally, we uncovered that 25-OH D alleviated prostate cell oxidative stress by triggering Nrf2 signaling. In conclusion, our data verified that 25-OH D regulated multiple singling pathways to restrain prostate cell EMT, proliferation, inflammation, and oxidative stress. Our study provides in vitro mechanical evidence to support clinical use of vitamin D as a treatment for BPH.

scholarly journals 250 Gambaran Benigna Prostat Hiperplasia di RSUP Prof. Dr. R. D. Kandou Manado Periode Januari 2014 – Juli 2017

e-CliniC ◽  
2017 ◽  
Vol 5 (2) ◽  
Author(s):  
Filzha Adelia ◽  
Alwin Monoarfa ◽  
Angelica Wagiu
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Transurethral Resection ◽  
Prostate Gland ◽  
Descriptive Study ◽  
Prostatic Hyperplasia ◽  
Transurethral Resection Of Prostate ◽  
Age Group ◽  
Flow Disturbance ◽  
Main Complaint ◽  
Common Action

Abstract: Benign prostatic hyperplasia (BPH) is defined as stromal cell proliferation of prostate gland which causes enlargement of the gland. It manifests as urine flow disturbance, difficult to urinate, and desire to urinate, however, the urine emission is low. In 2013, Indonesia has 9.2 million cases of BPH among men aged over 60 years. This study was aimed to obtain the profile of BPH cases at Prof. Dr. R. D. Kandou Hospital Manado in the period of January 2014 to June 2017. This was a retrospective descriptive study at Medical Record Installation of Prof. Dr. R. D. Kandou Hospital. The results showed that during that period of time, the highest percentage of cases was in 2016 (38.46%) and the most common age group was 61-70 years old (46.15%). The main complaint among the patients was difficult to urinate and the most frequently performed action was transurethral resection of prostate (TURP) (51.28%). Conclusion: In this study, BPH cases were most common at the age group 61-70 years old. Moreover, TURP was the most common action performed.Keywords: benign prostatic hyperplasia Abstrak: Benigna prostat hiperplasia (BPH) didefinisikan sebagai proliferasi dari sel stromal pada prostat, yang menyebabkan pembesaran kelenjar tersebut. Manifestasi BPH dapat berupa terganggunya aliran urin, sulit buang air kecil (BAK), dan keinginan buang air kecil namun pancaran urin lemah. Pada tahun 2013 di Indonesia terdapat 9,2juta kasus BPH, umumnya diderita laki-laki berusia di atas 60 tahun. Penelitian ini bertujuan untuk mendapatkan gambaran kasus BPH di RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2014 – Juli 2017. Jenis penelitian ialah deskriptif retrospektif , yang dilakukan di Instalasi Rekam Medik RSUP Prof. Dr. R. D. Kandou Manado. Hasil penelitian menunjukkan bahwa jumlah kasus BPH tertinggi pada tahun 2016 (38,46%) dan pada kelompok usia 61-70 tahun (46,15%). Keluhan utama semua pasien ialah sulit BAK. Tindakan yang paling sering digunakan yaitu transurethral resection of prostate (TURP) (51,28%). Simpulan: Kasus BPH terutama ditemukan berusia 61-70 tahun. Tindakan yang paling sering dilakukan yaitu reseksi prostat transuretra (TURP).Kata kunci: benigna prostat hiperplasia

Sign in / Sign up

Export Citation Format

Share Document